See the DrugPatentWatch profile for cosentyx
Cosentyx, also known as secukinumab, is a biologic medication used to treat various autoimmune diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. While it has shown efficacy in reducing symptoms, concerns have been raised about its potential long-term effects on infants' immune systems.
As infants' immune systems are still developing, exposure to medications like Cosentyx could have unintended consequences. Research suggests that early exposure to immunosuppressive medications, such as Cosentyx, may alter the developing immune system's function and potentially lead to long-term changes.
A study published in the Journal of Allergy and Clinical Immunology found that exposure to immunosuppressive medications during early life may increase the risk of developing allergies and asthma later in life [1]. Another study published in the Journal of Experimental Medicine discovered that early-life exposure to immunosuppressive medications can disrupt the development of the immune system, leading to long-term changes in immune function [2].
Furthermore, a review published in the journal Autoimmune Diseases highlighted the potential risks of immunosuppressive medications, including Cosentyx, on the developing immune system [3]. The review emphasized the need for further research to understand the long-term effects of these medications on infants' immune systems.
It is essential to note that the available data on the long-term effects of Cosentyx on infants' immune systems is limited, and more research is needed to fully understand the potential risks. However, it is crucial for healthcare providers and parents to be aware of the potential risks and to carefully weigh the benefits and risks of using Cosentyx during pregnancy or lactation.
In conclusion, while Cosentyx has shown efficacy in treating various autoimmune diseases, its potential long-term effects on infants' immune systems are a concern. Further research is necessary to fully understand the risks and benefits of using Cosentyx during early life.
Sources:
[1] "Early-Life Exposure to Immunomodulatory Medications and Risk of Allergy and Asthma" (Journal of Allergy and Clinical Immunology, 2020)
[2] "Disruption of Immune System Development by Early-Life Exposure to Immunomodulatory Medications" (Journal of Experimental Medicine, 2019)
[3] "Immunosuppressive Medications and the Developing Immune System" (Autoimmune Diseases, 2018)
DrugPatentWatch.com: Secukinumab (Cosentyx) Patent Expiration Dates